Synonyms: ZE46-0134
Compound class:
Synthetic organic
Comment: Lomonitinib is the INN for a tyrosine kinase inhibitor with antineoplastic potential. It appears to be the INN for Eilean Therapeutics' pan-FLT3/IRAK4 inhibitor (ZE46-0134) that is designed to simultaneously target clinically relevant resistance and activating FLT3 mutations and putative escape pathways (that arise via activation of IRAK4) in advanced AML [1].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
3-(3,4-dimethoxyphenyl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)pyrazolo[4,3-c]quinoline |
International Nonproprietary Names ![]() |
|
INN number | INN |
13355 | lomonitinib |
Synonyms ![]() |
ZE46-0134 |
Database Links ![]() |
|
CAS Registry No. | 2923221-56-9 (source: WHO INN record) |
GtoPdb PubChem SID | 507750383 |
PubChem CID | 171775678 |
Search Google for chemical match using the InChIKey | AAIAGDXMETYTJE-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | AAIAGDXMETYTJE |
Search PubMed clinical trials | lomonitinib |
Search PubMed titles | lomonitinib |
Search PubMed titles/abstracts | lomonitinib |
UniChem Compound Search for chemical match using the InChIKey | AAIAGDXMETYTJE-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | AAIAGDXMETYTJE-UHFFFAOYSA-N |